AMGN vs. GILD, MRNA, VRTX, ABBV, BMY, JNJ, LLY, MRK, PFE, and ALNY
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.
Amgen vs. Its Competitors
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.
In the previous week, Amgen had 4 more articles in the media than Gilead Sciences. MarketBeat recorded 50 mentions for Amgen and 46 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.45 beat Amgen's score of 1.29 indicating that Gilead Sciences is being referred to more favorably in the media.
83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.
Gilead Sciences has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
Gilead Sciences currently has a consensus target price of $115.39, indicating a potential upside of 0.73%. Amgen has a consensus target price of $304.43, indicating a potential upside of 10.14%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.
Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.4%. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Gilead Sciences and Amgen tied by winning 10 of the 20 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:AMGN) was last updated on 9/12/2025 by MarketBeat.com Staff
